Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

253009.pdf (789.94 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2020-07-19

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/211921

Emerging Agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1080/13543784.2020.1793955

Resum

ntroduction: Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasite Trypanosoma cruzi, is mostly diagnosed at its chronic phase when life-threatening symptomatology manifest in approximately 30% of those infected. Considering that both available drugs have variable efficacy by then, and there are over 6 million people infected, there is a pressing need to find safer, more efficacious drugs. Areas covered: We provide an updated view of the path to achieve the aforementioned goal. From state-of-the-art in vitro and in vivo assays based on genetically engineered parasites that have allowed high throughput screenings of large chemical collections, to the unfulfilled requirement of having treatment-response biomarkers for the clinical evaluation of drugs. In between, we describe the most promising pre-clinical hits and the landscape of clinical trials with new drugs or new regimens of existing ones. Moreover, the use of monkey models to reduce the pre-clinical to clinical attrition rate is discussed. Expert opinion: In addition to the necessary research on new drugs and much awaited biomarkers of treatment efficacy, a key step will be to generalize access to diagnosis and treatment and maximize efforts to impede transmission.

Matèries

Malaltia de Chagas, Malalties parasitàries

Matèries (anglès)

Chagas' disease, Parasitic diseases

Citació

Col·leccions

Articles publicats en revistes (Biologia, Sanitat i Medi Ambient)
Articles publicats en revistes (ISGlobal)

Citació

MARTINEZ-PEINADO, Nieves, et al. Emerging Agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?. Expert Opinion on Investigational Drugs. 2020. Vol. 29, num. 9, pags. 947-959. ISSN 1354-3784. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/211921

Exportar metadades

JSON - METS

Compartir registre